Evidence map›Paper›PMID 33349307›Full record

ArticleOncology research2020

Erratum.

Jing Zeng, Tianping Du, Yafeng Song, Yan Gao, Fuyan Li, Ruimin Wu, Yijia Chen, Wei Li, Hong Zhou, Yi Yang and 1 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Jing ZengDepartment of Infection Control, Taihe Hospital, Hubei University of MedicineShiyan, Hubei ProvinceP.R. China.
Tianping DuDepartment of Neurosurgery, Renmin Hospital, Hubei University of MedicineShiyan, Hubei ProvinceP.R. China.
Yafeng SongDepartment of PET Center and Institute of Anesthesiology and Pain, Taihe Hospital, Hubei University of MedicineShiyan, Hubei ProvinceP.R. China.
Yan GaoDepartment of PET Center and Institute of Anesthesiology and Pain, Taihe Hospital, Hubei University of MedicineShiyan, Hubei ProvinceP.R. China.
Fuyan LiDepartment of PET Center and Institute of Anesthesiology and Pain, Taihe Hospital, Hubei University of MedicineShiyan, Hubei ProvinceP.R. China.
Ruimin WuDepartment of PET Center and Institute of Anesthesiology and Pain, Taihe Hospital, Hubei University of MedicineShiyan, Hubei ProvinceP.R. China.
Yijia ChenDepartment of PET Center and Institute of Anesthesiology and Pain, Taihe Hospital, Hubei University of MedicineShiyan, Hubei ProvinceP.R. China.
Wei LiDepartment of PET Center and Institute of Anesthesiology and Pain, Taihe Hospital, Hubei University of MedicineShiyan, Hubei ProvinceP.R. China.
Hong ZhouDepartment of PET Center and Institute of Anesthesiology and Pain, Taihe Hospital, Hubei University of MedicineShiyan, Hubei ProvinceP.R. China.
Yi YangDepartment of PET Center and Institute of Anesthesiology and Pain, Taihe Hospital, Hubei University of MedicineShiyan, Hubei ProvinceP.R. China.
Zhijun PeiDepartment of PET Center and Institute of Anesthesiology and Pain, Taihe Hospital, Hubei University of MedicineShiyan, Hubei ProvinceP.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long noncoding RNA (lncRNA) colon cancer-associated transcript 2 (CCAT2) has been demonstrated to play an important role in diverse tumorigenesis. However, the biological function of lncRNAs in glioma is still unknown. In this study, we found that lncRNA CCAT2 was overexpressed in glioma tissues and cell lines and associated with tumor grade and size. Furthermore, patients with high levels of lncRNA CCAT2 had poorer survival than those with lower levels of lncRNA CCAT2. Knocking down lncRNA CCAT2 expression significantly suppressed the glioma cell growth, migration, and invasion, as well as induced early apoptosis of glioma cells in vitro. Moreover, lncRNA CCAT2 regulated epithelialmesenchymal transition (EMT)-associated gene expression. In conclusion, lncRNA CCAT2 plays an important role in glioma tumorigenesis and progression and may act as a potential biomarker for therapeutic strategy and prognostic prediction.

Identifiers

PMID33349307
PMCPMC7751219

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.